Geron shares edged lower in late trade

LOS ANGELES (MarketWatch) — Shares of Geron Corp. slipped Monday evening, slightly extending gain during the day during which the biotech and drug sector saw a raft of corporate-news developments.

Late-traded Geron shares
GERN, +0.48%
lost 0.6% to $5.64 after initially rising. The shares closed up 6.4% in dayside trade as the company enrolled its first patient in its early-stage clinical trial of human embryonic stem-cell treatment for injuries of the spinal cord.

Stock in Alexza Pharmaceuticals Inc.
ALXA
edged up a penny, or 0.7%, to $1.39 in evening trade. The shares tumbled during the day, down 54%, after the U.S. Food and Drug Administration declined to approve Alexza’s formulation of the drug loxapine to treat agitation in patients with schizophrenia or bipolar disorder.

Other formulations of loxapine have been on the market for several years. Read more in Biotech Stocks.

Also higher were evening-traded shares of Warner Chilcott
WCRX
, up 0.9% to $24.09 in low volume. The shares jumped 7.2% in the regular session after the pharmaceutical firm said the FDA has approved its postmenopausal osteoporosis treatment Atelvia.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.